Research study for those with moderate to severe Crohn’s disease

IRB/UVA Tracking #
20160
Principal Investigator
Anne G Tuskey
Contact
Lakin Underwood
Contact Phone
434.243.6156
Official Trial Title
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease (GS-US-419-3895)
Study Description

The Division of Gastroenterology and Hepatology seeks adults ages 18-75 with Crohn’s disease for a research study. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug called Filgotinib in treating people with moderate to severe active Crohn’s disease.

You may be eligible for this study if you have Crohn’s disease and it is not well controlled on the medications that you are currently taking.

The study involves taking an experimental medicine/placebo for 58 weeks, blood draws at each study visit, up to 3 colonoscopies, up to 21 visits during 70 weeks (including screening and follow-up).

Study-related insert exams, tests and experimental medication are all provided free of charge.

Compensation

No Compensation